Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04970082
Other study ID # 2021-A00947-34
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 17, 2021
Est. completion date August 31, 2022

Study information

Verified date May 2022
Source Centre Recherche Cardio Vasculaire Alpes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, non-inferiority, crossover investigation comparing the Direct Wire Pacing (DWP) versus standard method to measure Fractional Flow Reserve (FFR) in subjects with FFR indications. All subjects requiring on a clinical basis a pressure wire assessment of coronary artery stenosis(es) will be eligible to take part in the study.


Description:

Pressure wire-based Fractional Flow Reserve (FFR) has become the reference standard index of haemodynamic significance to guide revascularisation of intermediate coronary artery lesions. The FFR measurement determines the ratio of the maximum blood flow that can be achieved in a diseased or narrowed coronary artery to the maximum blood flow in a normal coronary artery. This ratio represents the potential decrease in distal coronary flow relative to coronary stenosis. FFR is easily measured during routine coronary angiography using a pressure wire to calculate the ratio of coronary pressure distal to a stenosis or diseased segment to aortic pressure under conditions of maximum myocardial hyperemia. An FFR of 1.0 is widely accepted as normal. An FFR of less than 0.80 is generally considered to be associated with coronary ischemia and widely accepted in favor of revascularization rather than conservative management. The current standard method of measuring FFR is to insert a pressure wire into the coronary artery while the hyperaemic agent, usually adenosine, is delivered by intracoronary bolus or continuous intravenous injection. Administration of adenosine may cause bradycardia and thus cause patient vagal discomfort. Direct Wire Pacing (DWP) can potentially overcome the drawbacks of the standard method when measuring FFR. Indeed, DWP allows to transmit an electrical current from the external pacemaker to the heart thanks to metallic FFR guidewire already used, and thus prevent bradycardia. In addition, there are some absolute contraindications to the use of Adenosine such as 2nd or 3rd degree atrioventricular block, untreated sinus dysfunction or long QT syndrome ...DWP could allow this highly recommended diagnostic tool (1A) to be used in this patient population. The investigators would therefore like to determine if the measurement of FFR by DWP would be non-inferior to the standard method to obtain precise FFR values and maximize patient's comfort.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date August 31, 2022
Est. primary completion date February 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Eligible patient for coronary angiography. Inclusion Criteria: The patients included in the study must meet the following inclusion criteria : - Patients = 18 years old - Patients with FFR indications - Has given consent to undergo diagnostic coronary procedure - Patients able to understand and provide informed consent - Patients with Social Security coverage Prior to randomisation: Angiography demonstrates at least one coronary stenosis in an artery, requiring FFR measurement for physiological assessment. Exclusion Criteria: The patients included in the study should not meet the following inclusion criteria : - Contraindications to use sensitivity to Adenosine or any of its excipients - Technically inaccessible stenosis(es) - Pregnant or breastfeeding woman - Patients under judicial protection, tutorship or curatorship - Patient participating in another interventional clinical trial

Study Design


Intervention

Diagnostic Test:
FFR DWP
FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
FFR
FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.

Locations

Country Name City State
France Groupe Hospitalier Mutualiste de Grenoble Grenoble

Sponsors (1)

Lead Sponsor Collaborator
Centre Recherche Cardio Vasculaire Alpes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reproducibility of the FFR measurement Evaluated by the number of patients with comparable FFR ratio recording. The FFR ratio should remain constant (+/-0.02) between the two modes of measuring FFR. Intraoperative
Secondary Number of participants with Adverse Events Assessed by the number of participants with adverse events during the procedure. Intraoperative
Secondary Tolerance Assessed by asking patients during each FFR to grade verbally any symptoms of chest discomfort. Intraoperative
Secondary correlation between a disproportionately high FFR value and la presence of a (partially) infarcted territory The correlation between a disproportionately high FFR value in presence of a (partially)infarcted territory will be assessed by the comparison the obtained FFR value, the degree of angiographic stenosis measured and the obtained stimulation threshold. Intraoperative
See also
  Status Clinical Trial Phase
Recruiting NCT05133843 - Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis N/A
Completed NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01332591 - Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy. N/A
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00739466 - Biorest Liposomal Alendronate With Stenting sTudy (BLAST) Phase 2
Completed NCT01310309 - EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Completed NCT00531011 - EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Not yet recruiting NCT06052670 - Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions
Completed NCT05509296 - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease N/A
Not yet recruiting NCT05393882 - Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
Recruiting NCT06397820 - Relation Between AI-QCA and Cardiac PET
Active, not recruiting NCT01960504 - First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II) N/A
Completed NCT01721096 - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Active, not recruiting NCT01342822 - Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Phase 4
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Recruiting NCT05532605 - Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i N/A
Completed NCT02066623 - Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
Not yet recruiting NCT02946320 - Optimal Predilatation Technique for BVS Implantation Phase 3
Terminated NCT01136915 - Kidney Damage In Patients With Severe Fall In eGFR Phase 4
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study